| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b8e71233d46c313ac971fc4f9e4aa4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0637993708bbd3f62ac790bcdf29c2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85465399e60c80e7fe42026c69a8d3f1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2004-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaf1be268fcdd282090c8e40317af21e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_742f278bc64aebbeee0c50f328158fb2 |
| publicationDate |
2004-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004090113-A2 |
| titleOfInvention |
L53, a lung cancer associated antigen and uses thereof |
| abstract |
The present invention relates to L53 genes and gene products that are differentially expressed in cancer tissues and cell lines. In a particular aspect of the invention, L53 genes and gene products are differentially expressed in lung cancer tissues and cell lines. In accordance with the present invention, L53 nucleic acid sequences, amino acid sequences and antibodies thereto, and methods of use thereof are presented. The L53 molecules and methods of the invention may be used to monitor expression levels of L53, wherein the detection of aberrant levels of L53 molecules provides a positive diagnostic indicator of lung cancer and/or other L53 associated cancers and a useful prognostic indice of the state of the diseases. Also provided are compounds capable of modulating L53 activity, which are identified using the L53 molecules and methods of the invention. Such L53 modulating compounds may be used efficaciously to treat patients with lung cancer, or other L53 antigen positive cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10640508-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918735-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918627-B2 |
| priorityDate |
2003-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |